09 August 2017
Visiongain has launched a new pharma report World Marine Derived Drugs Market Forecast 2017-2027: Prospects by Drug Type (Phenol, Steroid, Ether, Peptide, Other), Source (Algae, Invertebrate, Microorganism), Application (Anti-Microbial, Anti-Tumour, Cardiovascular, Anti-Viral, Anti-Inflammatory), and Geography
Marine derived drugs are one of the major accomplishments of the 20th century in the development of modern pharmaceuticals. The marine biosphere is the largest on earth and harbours an enormous number of different organisms. Marine plants, animals, and microbes produce compounds that have potential as pharmaceuticals. Living conditions differ fundamentally from those in the terrestrial environment. The production of specific secondary metabolites is an important adaptation mechanism of marine organisms in order to survive in the sea.
Aquaculture is well established for the production of marine animals like fishes or some mussels for food and for macroalgae. Cultivation in bioreactors is realized for macro- and microalgae, some types of invertebrate cells, marine fungi and several species of marine bacteria. However, the majority of pharmaceutically interesting marine organisms, especially microorganisms, cannot be cultured under artificial conditions. Better understanding of living conditions in natural environment is necessary to develop alternative cultivation methods and to maintain the metabolite production over a long time. One promising way could be the co-cultivation, also called mixed fermentation, of two or more different organisms, mainly microorganisms, which tries to mimic the complex communities in nature.
Worldwide, tumour causing diseases are the third most common cause of death in mortality statistics. New anti-tumour drugs with high activity and minimized side effects are urgently needed. Marine natural compounds can contribute to meet this demand. The development of marine cytostatics started with the already mentioned discovery of the nucleosides spongothymidine and spongouridine from the Caribbean sponge Tethya crypta.
The lead Visiongain report analyst for this report commented; “The marine biosphere is the largest on earth and harbours an enormous number of different organisms. Living conditions differ fundamentally from those in terrestrial environment. The production of specific secondary metabolites is an important adaption mechanism of marine organisms to survive in the sea.
These metabolites possess biological activities which make them interesting as possible drugs for humans. Some of the applications of marine drugs include the treatment of viral diseases, chronic pain and lowering triglyceride levels in blood. Some other products are of interest in diagnostic and as experimental tools.
Marine derived drugs are used in different clinical conditions such as cancer, cardiovascular disorders, antiviral, anti-inflammatory, and others. A significant number of marine bioproducts with pharmaceutical potential have been identified from heterotrophic marine microorganisms isolated from coastal sediments. In addition, some marine bioproducts originally isolated from organisms such as sponges, have been subsequently discovered to be localized in microbial associates. Recent U.S. legislation and executive directives support a renewed emphasis on exploring the vast unknown areas of our oceans, discovering species new to science, identifying marine resources with potential medicinal value, and ensuring the protection and sustained use of these resources.”
The Marine-derived drugs market is highly competitive with many different players entering the market. The report discusses selected leading companies in the market. Notable companies in the Marine-derived drugs market include Abbott Laboratories, GlaxoSmithKline, Abbvie, Pharma Marine AS, Takeda Pharmaceutical Company, Aker BioMarine AS, Marine Polymer Technologies Inc., Sea Run Holdings, Aphios Corporation and Sanofi S.A.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market for ophthalmic drugs is a growing one.
17 June 2019
Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.
14 June 2019
The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.
06 June 2019
Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.